Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
O14653
UPID:
GOSR2_HUMAN
Alternative names:
27 kDa Golgi SNARE protein; Membrin
Alternative UPACC:
O14653; D3DXJ5; D3DXJ6; Q8N4B8; Q96DA5; Q9BZZ4
Background:
Golgi SNAP receptor complex member 2, also known as Membrin and 27 kDa Golgi SNARE protein, plays a crucial role in the transport of proteins from the cis/medial-Golgi to the trans-Golgi network. Its unique function is pivotal in maintaining cellular homeostasis and protein processing.
Therapeutic significance:
Linked to diseases such as Epilepsy, progressive myoclonic 6, and congenital muscular dystrophy with or without seizures, understanding the role of Golgi SNAP receptor complex member 2 could open doors to potential therapeutic strategies. These conditions highlight the protein's significance in neurodevelopment and muscle function.